Dr. Mar Tormo Díaz

Principal Investigator
Research Group on Myeloid Neoplasms

Presentation

María del Mar Tormo Díaz es médico facultativo especialista en hematología y profesora asociada de la Universidad de Valencia. Forma parte del Instituto de Investigación Sanitaria INCLIVA de Valencia, desde su constitución y acreditación en el año 2011.

En la actualidad es la responsable del grupo de neoplasias mieloides dentro de la línea de Cáncer del INCLIVA.Su actividad investigadora se ha centrado en el estudio de las leucemias agudas y síndromes mielodisplásicos. En concreto, las líneas de investigación principales desarrolladas en los últimos años han sido en el estudio de polimorfismos genéticos implicados en el desarrollo de leucemias agudas y síndromes mielodisplásicos secundarios a tóxicos, el estudio de nuevos factores pronósticos biológicos en leucemia aguda mieloblástica, el impacto de mutaciones específicas en el tratamiento de los síndromes mielodisplásicos y leucemias agudas mieloides tratadas con agentes hipometilantes.

Posee un profundo conocimiento de la patología mieloide, su biología, expresión clínica, manejo y herramientas terapéuticas disponibles. Forma parte de varios grupos cooperativos nacionales de reconocido prestigio como son el grupo CETLAM (Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplásias), PETHEMA (Programa Español de Tratamientos en Hematología) y GESMD (Grupo español de Síndromes Mielodisplásicos) con una importante actividad científica dentro de ellos.

Dra. Mar Tormo Díaz
Principal
Investigator
Dr. Mar Tormo Díaz

maria.mar.tormo@uv.es; tormo_mar@gva.es

Publications
Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry. Martinez-Cuadron D, Megias-Vericat J, Gil C, Bernal T, Tormo M, Martinez-Sanchez P, Rodriguez-Medina C, Serrano J, Herrera P, Simon J, Sayas M, Bergua J, Lavilla-Rubira E, Amigo M, Benavente C, Lorenzo J, Perez-Encinas M, Vidriales M, Colorado M, De Rueda B, Garcia-Boyero R, Marini S, Garcia-Suarez J, Lopez-Pavia M, Gomez-Roncero M, Noriega V, Lopez A, Labrador J, Cabello A, Sossa C, Algarra L, Stevenazzi M, Solana-Altabella A, Boluda B, Montesinos P. Haematologica. 2024 Jan 1;109(1):115-128. doi: 10.3324/haematol.2022.282506. PMID: 37199127

Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Roca J, Cassaday R, Böll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, Díaz M, Vucinic V, González-Campos J, Rambaldi A, Schwartz S, Berthon C, Hernández-Rivas J, Gordon P, Brüggemann M, Hamidi A, Chen Y, Wong H, Panwar B, Katlinskaya Y, Markovic A, Kantarjian H. American Journal of Hematology. 2024 Feb 5. doi: 10.1002/ajh.27227. PMID: 38317420

Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: a proof-of-concept study. de la Asunción C, Giménez E, Hernández-Boluda J, Terol M, Albert E, López J, García-Gutiérrez V, Andreu R, Malo M, Fox M, Remigia M, Amat P, Solano C, Navarro D. Journal of Medical Virology. 2023 Jul;95(7):e28933. doi: 10.1002/jmv.28933. PMID: 37403897

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Sargas C, Ayala R, Larrayoz M, Chillon M, Rodriguez-Arboli E, Bilbao C, Prados de la Torre E, Martinez-Cuadron D, Rodriguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua J, Algarra L, Tormo M, Martinez-Sanchez P, Soria E, Serrano J, Alonso-Dominguez J, Garcia R, Amigo M, Herrera-Puente P, Sayas M, Lavilla-Rubira E, Martinez-Lopez J, Calasanz M, Garcia-Sanz R, Perez-Simon J, Gomez Casares M, Sanchez-Garcia J, Barragan E, Montesinos P. Blood Cancer Journal. 2023 May 12;13(1):77. doi: 10.1038/s41408-023-00835-5. PMID: 37173322

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials. Gonzalez-Gil C, Morgades M, Lopes T, Fuster-Tormo F, Garcia-Chica J, Zhao R, Montesinos P, Torrent A, Diaz-Beya M, Coll R, Hermosin L, Mercadal S, Gonzalez-Campos J, Zamora L, Artola T, Vall-Llovera F, Tormo M, Gil-Cortes C, Barba P, Novo A, Ribera J, Bernal T, De Ugarriza P, Queipo M, Martinez-Sanchez P, Gimenez A, Gonzalez-Martinez T, Cladera A, Cervera J, Fernandez-Martin R, Ardaiz M, Vidal M, Baena A, Lopez-Bigas N, Bigas A, Maciejewski J, Orfao A, Ribera J, Genesca E. Haematologica. 2023 Apr 1;108(4):969-980. doi: 10.3324/haematol.2022.281196. PMID: 36325893

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia. Kayser S, Martinez-Cuadron D, Rodriguez-Veiga R, Hanel M, Tormo M, Schafer-Eckart K, Botella C, Stolzel F, Del Castillo TB, Keller U, Rodriguez-Medina C, Held G, Amigo ML, Schliemann C, Colorado M, Kaufmann M, Garcia MB, Krause SW, Gorner M, Jost E, Steffen B, Zukunft S, Platzbecker U, Ho AD, Baldus CD, Serve H, Muller-Tidow C, Thiede C, Bornhauser M, Montesinos P, Rollig C, Schlenk RF. Haematologica. 2023 Aug 1;108(8):2059-2066. doi: 10.3324/haematol.2022.282127. PMID: 36815361

Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion. Martin Castillo I, Villamon Ribate E, Calabuig Munoz M, Sanz Santillana G, Such Taboada E, Mora Castera E, Calasanz Abinzano MJ, Irigoyen Barranco A, Collado Nieto R, Vara Pampliega M, Blanco ML, Alvarez de Andres S, Perez de Oteyza J, Bernal del Castillo T, Granada Font I, Jerez Cayuela A, Diez-Campelo M, Abellan Sanchez R.; Solano Vercet C, Tormo Diaz M. Cancer Medicine. 2023 Aug;12(16):16788-16792. doi: 10.1002/cam4.6300. PMID: 37403747

Machine learning improves risk stratification in myelodysplastic neoplasms: an analysis of the Spanish Group of Myelodysplastic Syndromes. Mosquera Orgueira A, Perez Encinas M, Diaz Varela N, Mora E, Diaz-Beya M, Montoro M, Pomares H, Ramos F, Tormo M, Jerez A, Nomdedeu J, De Miguel Sanchez C, Leonor A, Carcel P, Cedena Romero M, Xicoy B, Rivero E, Del Orbe Barreto R, Diez-Campelo M, Benlloch L, Crucitti D, Valcarcel D. HemaSphere. 2023 Oct 11;7(10):e961. doi: 10.1097/HS9.0000000000000961. PMID: 37841754

Molecular landscape and validation of new genomic classification in 2668 Adult AML Patients: real life data from the PETHEMA Registry. Sargas C, Ayala R, Larrayoz MJ, Chillon MC, Carrillo-Cruz E, Bilbao-Sieyro C, Prados de la Torre E, Martinez-Cuadron D, Rodriguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua JM, Algarra L, Tormo M, Martinez-Sanchez P, Soria E, Serrano J, Alonso-Dominguez JM, Garcia-Boyero R, Amigo ML, Herrera-Puente P, Sayas MJ, Lavilla-Rubira E, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R, Perez-Simon JA, Gomez-Casares MT, Sanchez-Garcia J, Barragan E, Montesinos P, on behalf of Pethema Group. Cancers. 2023 Jan 10;15(2):438. doi: 10.3390/cancers15020438. PMID: 36672386

SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. Pinana J, Martino R, Vazquez L, Lopez-Corral L, Perez A, Chorao P, Avendano Pita A, Pascual M, Sanchez Salinas A, Sanz Linares G, Olave M, Arroyo I, Tormo M, Villalon L, Conesa Garcia V, Gago B, Terol M, Villalba M, Garcia Gutierrez V, Cabero A, Hernandez Rivas J, Ferrer E, Garcia Cadenas I, Teruel A, Navarro D, Cedillo A, Sureda A, Solano C. Bone Marrow Transplantation. 2023 Feb 28;1-14. doi: 10.1038/s41409-023-01946-0. PMID: 36854892

Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. Onate G, Pratcorona M, Garrido A, Artigas-Baleri A, Bataller A, Tormo M, Arnan M, Vives S, Coll R, Salamero O, Vall-Llovera F, Sampol A, Garcia A, Cervera M, Avila S, Bargay J, Ortin X, Nomdedeu J, Esteve J, Sierra J. Blood Cancer Journal. 2023 May 5;13(1):69. doi: 10.1038/s41408-023-00839-1. PMID: 37147301

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia. Simoes C, Villar S, Ariceta B, Garces J, Burgos L, Alignani D, Sarvide S, Martinez-Cuadron D, Bergua J, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez-Lorenzo J, Vidriales M, Chillon C, Labrador J, Falantes J, Sayas M, Ayala R, Martinez-Lopez J, Pierola A, Calasanz M, Prosper F, San-Miguel J, Sanz M, Paiva B, Montesinos P. British Journal of Haematology. 2023 Jun;201(6):1239-1244. doi: 10.1111/bjh.18815. PMID: 37057357

5′-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics. Diaz-Santa J, Rodriguez-Romanos R, Coll R, Osca G, Pratcorona M, Gonzalez-Bartulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Diez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D. European Journal of Haematology. 2022 Dec;109(6):755-764. doi: 10.1111/ejh.13862. PMID: 36063368

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O’Connor T, Previtali A, Rose S, Garcia-Manero G. Blood Advances. 2022 Apr 12;6(7):2207-2218. doi: 10.1182/bloodadvances.2021005487. PMID: 34972214

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig DC, Tormo M, Voso MT, Cavenagh J, O’Connor T, Previtali A, Rose S, Silverman LR. Blood advances. 2022 Apr 12;6(7):2219-2229. doi: 10.1182/bloodadvances.2021006138. PMID: 34933333

Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: a series of 372 patients from the PETHEMA AML registry. Hernandez Boluda JC, Martinez Cuadron D, Pereira A, Rodriguez Veiga R, Boluda B, Gil C, Casal-Marini S, Serrano J, Martinez Lopez J, Bergua J, Algarra L, Bernal T, Lopez Lorenzo JL, Colorado M, Lopez A, Tormo M, Sayas MJ, Trigo F, Lopez Pavia M, Perez Simon JA, Lavilla Rubira E, Rodriguez Medina C, Rodriguez Gutierrez JI, Sanz Caballer MA, Montesinos P. Leukemia Research. 2022 Mar 6;115:106821. doi: 10.1016/j.leukres.2022.106821. PMID: 35286939

Azacitidine vs. Decitabine in unfit newly diagnosed acute myeloid leukemia patients: results from the PETHEMA Registry. Labrador J, Martinez-Cuadron D, de la Fuente A, Rodriguez-Veiga R, Serrano J, Tormo M, Rodriguez-Arboli E, Ramos F, Bernal T, Lopez-Pavia M, Trigo F, Martinez-Sanchez MP, Rodriguez-Gutierrez JI, Rodriguez-Medina C, Gil C, Garcia Belmonte D, Vives S, Foncillas MA, Perez-Encinas M, Novo A, Recio I, Rodriguez-Macias G, Bergua JM, Noriega V, Lavilla E, Roldan-Perez A, Sanz MA, Montesinos P, on Behalf of Pethema Group. Cancers. 2022 May 9;14(9):2342. doi: 10.3390/cancers14092342. PMID: 35565471

Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Piñana JL, Garcia-Sanz R, Martino R, Garcia-Roa M, Martin-Martin GA, Risco-Gálvez I, Tormo M, Martinez-Barranco P, Marcos-Corrales S, Calabuig M, Conesa V, Teruel A, Ruiz-Pérez S, Solano C, Navarro D, Cedillo Á, Sureda A. Blood Advances. 2022 Jan 8;6(3):848-853. doi: 10.1182/bloodadvances.2021006326. PMID: 34905620

Characteristics and outcomes of adult patients in the PETHEMA Registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia. Martinez-Cuadron D, Serrano J, Mariz J, Gil C, Tormo M, Martinez-Sanchez P, Rodriguez-Arboli E, Garcia-Boyero R, Rodriguez-Medina C, Martinez-Chamorro C, Polo M, Bergua J, Aguiar E, Amigo M, Herrera P, Alonso-Dominguez J, Bernal T, Espadana A, Sayas M, Algarra L, Vidriales M, Vasconcelos G, Vives S, Perez-Encinas M, Lopez A, Noriega V, Garcia-Fortes M, Chillon M, Rodriguez-Gutierrez J, Calasanz M, Labrador J, Lopez J, Boluda B, Rodriguez-Veiga R, Martinez-Lopez J, Barragan E, Sanz M, Montesinos P. Cancers. 2022 Jun 6;14(11):2817. doi: 10.3390/cancers14112817. PMID: 35681796

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Bataller A, Garrido A, Guijarro F, Onate G, Diaz-Beya M, Arnan M, Tormo M, Vives S, de Llano M, Coll R, Gallardo D, Vall-Llovera F, Escoda L, Garcia-Guinon A, Salamero O, Sampol A, Merchan B, Bargay J, Castano-Diez S, Esteban D, Oliver-Caldes A, Rivero A, Mozas P, Lopez-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu J, Colomer D, Brunet S, Sierra J, Esteve J. Blood advances. 2022 Feb 22;6(4):1193-1206. doi: 10.1182/bloodadvances.2021005585. PMID: 34911079

Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice. Montoro MJ, Pomares H, Coll R, Bernal Del Castillo T, Tormo M, Jimenez A, Brunet S, Casano J, Oiartzabal I, Diez-Campelo M, Ramos F, Romero R, Salido-Fierrez E, Pedro C, Bargay J, Munoz-Novas C, Lopez R, Rafel M, Valcarcel D. Leukemia & Lymphoma. 2022 Dec 28;1-12. doi: 10.1080/10428194.2022.2154604. PMID: 36577016

Impact of center-related characteristics and macroeconomic factors on the outcome of adult patients with acute lymphoblastic leukemia treated with pediatric-inspired protocols. Barba P, Morgades M, Montesinos P, Gonzalez-Campos J, Torrent A, Gil C, Bernal T, Tormo M, Mercadal S, Novoa S, Garcia-Cadenas I, Queipo de Llano MP, Cervera M, Coll R, Bermudez A, Amigo ML, Monsalvo S, Esteve J, Garcia-Boyero R, Novo A, Hernandez Rivas JM, Cladera A, Martinez-Sanchez P, Serrano J, Artola MT, Soria B, Abella E, Vall-Llovera F, Bergua J, Herrera P, Barrios D, Ribera JM. Hemasphere. 2022 Dec 23;7(1):e810. doi: 10.1097/HS9.0000000000000810. PMID: 36583094

Impact of FLT3-ITD mutation status and its ratio in a cohort of 2901 patients undergoing upfront intensive chemotherapy: a PETHEMA Registry Study. Ayala R, Carreno-Tarragona G, Barragan E, Boluda B, Larrayoz M, Chillon M, Carrillo-Cruz E, Bilbao C, Sanchez-Garcia J, Bernal T, Martinez-Cuadron D, Gil C, Serrano J, Rodriguez-Medina C, Bergua J, Perez-Simon J, Calbacho M, Alonso-Dominguez J, Labrador J, Tormo M, Amigo M, Herrera-Puente P, Rapado I, Sargas C, Vazquez I, Calasanz M, Gomez-Casares T, Garcia-Sanz R, Sanz M, Martinez-Lopez J, Montesinos P. Cancers. 2022 Nov 24;14(23):5799. doi: 10.3390/cancers14235799. PMID: 36497281

Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Guijarro F, Bataller A, Diaz-Beya M, Garrido A, Coll-Ferra C, Vives S, Salamero O, Valcarcel D, Tormo M, Arnan M, Sampol A, Castano-Diez S, Martinez C, Suarez-Lledo M, Fernandez-Aviles F, Hernandez-Boluda J, Ribera J, Rovira M, Brunet S, Sierra J, Esteve J. Bone Marrow Transplantation. 2022 Aug;57(8):1304-1312. doi: 10.1038/s41409-022-01703-9. PMID: 35643942

Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients. Torres I, Huntley D, Tormo M, Calabuig M, Hernandez-Boluda J, Terol M, Carretero C, de Michelena P, Perez A, Pinana J, Colomina J, Solano C, Navarro D. BMC Infectious Diseases. 2022 Feb 21;22(1):172. doi: 10.1186/s12879-022-07154-3. PMID: 35189833

Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin. Sangerman M, Moreno A, Quintana A, Garcia-Vidal C, Rubio M, Diaz M, Vendranas M, Macias G. Expert Review of Hematology. 2022 Mar;15(3):203-214. doi: 10.1080/17474086.2022.2054801. PMID: 35332831

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. Ribera J, Granada I, Morgades M, Gonzalez T, Ciudad J, Such E, Calasanz M, Mercadal S, Coll R, Gonzalez-Campos J, Tormo M, Garcia-Cadenas I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermudez A, Orfao A, Ribera J, Programa Tratamiento Hemopatias Ma, Spanish Soc Hematology, SEHH. British Journal of Haematology. 2022 Feb;196(3):670-675. doi: 10.1111/bjh.17844. PMID: 34549416

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Onate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol MA, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M. Blood Advances. 2022 Feb 8;6(3):882-890. doi: 10.1182/bloodadvances.2020004136. PMID: 34516636

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Pinana JL, Lopez-Corral L, Martino R, Vazquez L, Perez A, Martin-Martin G, Gago B, Sanz-Linares G, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave MT, Corona M, Marcos-Corrales S, Tormo M, Hernandez-Rivas JA, Montoro J, Rodriguez-Fernandez A, Risco-Galvez I, Rodriguez-Belenguer P, Hernandez-Boluda JC, Garcia-Cadenas I, Ruiz-Garcia M, Munoz-Bellido JL, Solano C, Cedillo A, Sureda A, Navarro D. Journal of Hematology & Oncology. 2022 May 7;15(1):54. doi: 10.1186/s13045-022-01275-7. PMID: 35526045

Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Pinana J, Vazquez L, Martino R, de la Camara R, Sureda A, Rodriguez-Veiga R, Garrido A, Sierra J, Ribera J, Torrent A, Mateos M, de la Rubia J, Tormo M, Diez-Campelo M, Garcia-Gutierrez V, Alvarez-Larran A, Sancho J, MartinGarcia-Sancho A, Yanez L, Simon J, Barba P, Abrisqueta P, Alvarez-Twose I, Bonanad S, Lecumberri R, Ruiz-Camps I, Navarro D, Hernandez-Rivas J, Cedillo A, Garcia-Sanz R, Bosch F. Leukemia & Lymphoma. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. PMID: 34668835

The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients. Villar S, Ariceta B, Agirre X, Urribarri A, Ayala R, Martinez-Cuadron D, Bergua J, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Simoes C, Herrera P, Calasanz M, Alfonso-Pierola A, Paiva B, Martinez-Lopez J, San Miguel J, Prosper F, Montesinos P. Frontiers in Oncology. 2022 Nov 24;12:1054458. doi: 10.3389/fonc.2022.1054458. PMID: 36505804

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Martinez-Cuadron D, Megias-Vericat JE, Serrano J, Martinez-Sanchez P, Rodriguez-Arboli E, Gil C, Aguiar E, Bergua Burgues JM, Lopez-Lorenzo JL, Bernal T, Espadana A, Colorado M, Rodriguez-Medina C, Lopez-Pavia M, Tormo M, Algarra JL, Amigo ML, Sayas MJ, Labrador J, Rodriguez-Gutierrez JI, Benavente C, Costilla-Barriga L, Garcia-Boyero R, Lavilla E, Vives S, Herrera P, Garcia D, Herraez-Albendea MM, Esteves GV, Gomez-Roncero MI, Cabello A, Bautista G, Balerdi A, Mariz J, Boluda B, Sanz MA, Montesinos P. Blood Advances. 2022 Feb 22;6(4):1278-1295. doi: 10.1182/bloodadvances.2021005335. PMID: 34794172

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Labrador J, Saiz-Rodriguez M, de Miguel D, de Laiglesia A, Rodriguez-Medina C, Vidriales M, Perez-Encinas M, Sanchez-Sanchez M, Cuello R, Roldan-Perez A, Vives S, Benzo-Callejo G, Colorado M, Garcia-Fortes M, Sayas M, Olivier C, Recio I, Conde-Royo D, Bienert-Garcia A, Vahi M, Munoz-Garcia C, Seri-Merino C, Tormo M, Vall-Llovera F, Foncillas M, Martinez-Cuadron D, Sanz M, Montesinos P. Cancers. 2022 Mar 29;14(7):1734. doi: 10.3390/cancers14071734. PMID: 35406512

A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Vives S, Martinez-Cuadron D, Bergua Burgues J, Algarra L, Tormo M, Martinez-Sanchez M, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Lopez-Lorenzo J, Gil C, Vidriales B, Falantes J, Serrano A, Labrador J, Sayas M, Foncillas M, Amador Barciela M, Olave M, Colorado M, Gascon A, Fernandez M, Simiele A, Perez-Encinas M, Rodriguez-Veiga R, Garcia O, Martinez-Lopez J, Barragan E, Paiva B, Sanz M, Montesinos P, PETHEMA Group. Cancer. 2021 Jun 15;127(12):2003-2014. doi: 10.1002/cncr.33403. PMID: 33626197

Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Genesca E, Morgades M, Gonzalez-Gil C, Fuster-Tormo F, Haferlach C, Meggendorfer M, Montesinos P, Barba P, Gil C, Coll R, Moreno MJ, Martinez-Carballeira D, Garcia-Cadenas I, Vives S, Ribera J, Gonzalez-Campos J, Diaz-Beya M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermudez A, Vall-Llovera F, Martinez-Sanchez P, Amigo ML, Monsalvo S, Novo A, Cervera M, Garcia-Guinon A, Ciudad J, Cervera J, Hernandez-Rivas JM, Granada I, Haferlach T, Orfao A, Sole F, Ribera JM. Leukemia Research. 2021 Jun 8;109:106612. doi: 10.1016/j.leukres.2021.106612. PMID: 34139642

Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia. Ribera J, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesca E, Barba P, Ribera J, Garcia Cadenas I, Moreno M, Martinez-Carballeira D, Torrent A, Martinez-Sanchez P, Monsalvo S, Gil C, Tormo M, Artola M, Cervera M, Gonzalez-Campos J, Rodriguez-Medina C, Bermudez A, Novo A, Soria B, Coll R, Amigo M, Lopez A, Fernandez Martin R, Serrano J, Mercadal S, Cladera A, Gimenez-Conca A, Penarrubia M, Abella E, Vall-Llovera F, Hernandez-Rivas J, Garcia A, Bergua Burgues J, de Rueda B, Sanchez-Sanchez M, Serrano A, Calbacho M, Alonso Vence N, Mendez-Sanchez J, Garcia-Boyero R, Olivares M, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, Orfao A. Blood. 2021 Apr 8;137(14):1879-1894. doi: 10.1182/blood.2020007311. PMID: 33150388

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. Cabezon M, Malinverni R, Bargay J, Xicoy B, Marce S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, Jimenez M, Hoyos M, Valcarcel D, Escoda L, Vall-Llovera F, Garcia A, Font L, Ramila E, Buschbeck M, Zamora L, CETLAM Grp. Clinical Epigenetics. 2021 Jan 14;13(1):9. doi: 10.1186/s13148-021-01002-y. PMID: 33446256

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. Boluda B, Martinez-Cuadron D, Algarra L, Cano I, Sayas M, Acuna-Cruz E, Blanco A, Marco-Ayala J, DeLapuerta R, Diaz-Gonzalez A, Tormo M, Rodriguez-Veiga R, Garcia R, Pinana J, Lopez-Pavia M, Barragan E, Amigo M, Sargas C, Lopez A, Solana-Altabella A, Gil C, Megias-Vericat J, Sanz M, Montesinos P. Leukemia & Lymphoma. 2021 Nov;62(11):2727-2736. doi: 10.1080/10428194.2021.1938031. PMID: 34121593

Evolving treatment patterns and outcomes in older patients (?60 years) with AML: changing everything to change nothing?. Martinez-Cuadron D, Serrano J, Gil C, Tormo M, Martinez-Sanchez P, Perez-Simon J, Garcia-Boyero R, Rodriguez-Medina C, Lopez-Pavia M, Benavente C, Bergua J, Lavilla-Rubira E, Amigo M, Herrera P, Alonso-Dominguez J, Bernal T, Colorado M, Sayas M, Algarra L, Vidriales M, Rodriguez-Macias G, Vives S, Perez-Encinas M, Lopez A, Noriega V, Garcia-Fortes M, Ramos F, Rodriguez-Gutierrez J, Costilla-Barriga L, Labrador J, Boluda B, Rodriguez-Veiga R, Martinez-Lopez J, Sanz M, Montesinos P. Leukemia. 2021 Jun;35(6):1571-1585. doi: 10.1038/s41375-020-01058-4. PMID: 33077867

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Simoes C, Paiva B, Martinez-Cuadron D, Bergua J, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez J, Vidriales M, Labrador J, Falantes J, Sayas M, Ayala R, Martinez-Lopez J, Villar S, Calasanz M, Prosper F, San-Miguel J, Sanz M, Montesinos P. Blood Advances. 2021 Feb 9;5(3):760-770. doi: 10.1182/bloodadvances.2020003195. PMID: 33560390

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. Martin I, Villamon E, Abellan R, Calasanz M, Irigoyen A, Sanz G, Such E, Mora E, Gutierrez M, Collado R, Garcia-Serra R, Vara M, Blanco M, Oiartzabal I, Alvarez S, Bernal T, Granada I, Xicoy B, Jerez A, Calabuig M, Diez R, Gil A, Diez-Campelo M, Solano C, Tormo M, Spanish Grp Myelodysplastic Syn. British Journal of Haematology. 2021 Aug;194(4):708-717. doi: 10.1111/bjh.17675. PMID: 34296432

Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML Project. Sargas C, Ayala R, Chillon M, Larrayoz M, Carrillo-Cruz E, Bilbao C, Yebenes-Ramirez M, Llop M, Rapado I, Garcia-Sanz R, Vazquez I, Soria E, Florido-Ortega Y, Janusz K, Botella C, Serrano J, Martinez-Cuadron D, Bergua J, Amigo M, Martinez-Sanchez P, Tormo Diaz M, Bernal T, Herrera-Puente P, Garcia R, Algarra L, Sayas M, Costilla-Barriga L, Perez-Santolalla E, Marchante I, Lavilla-Rubira E, Noriega V, Alonso-Dominguez J, Sanz M, Sanchez-Garcia J, Gomez-Casares M, Perez-Simon J, Calasanz M, Gonzalez-Diaz M, Martinez-Lopez J, Barragan E, Montesinos P. Haematologica. 2021 Dec 1;106(12):3079-3089. doi: 10.3324/haematol.2020.263806. PMID: 33179471

Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020). Kayser S, Rahme R, Martinez-Cuadron D, Ghiaur G, Thomas X, Sobas M, Guerci-Bresler A, Garrido A, Pigneux A, Gil C, Raffoux E, Tormo M, Vey N, de la Serna J, Salamero O, Lengfelder E, Levis MJ, Fenaux P, Sanz MA, Platzbecker U, Schlenk RF, Ades L, Montesinos P. Leukemia. 2021 Dec;35(12):3631. doi: 10.1038/s41375-021-01358-3. PMID: 34785795

Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. Ribera J, Morgades M, Genesca E, Chapchap E, Montesinos P, Acuna-Cruz E, Gil C, Garcia-Cadenas I, Barba P, Gonzalez-Campos J, de Llano M, Torrent A, Ribera J, Granada I, Bernal T, Diaz-Beya M, Amigo M, Coll R, Tormo M, Vall-llovera F, Gomez-Centurion I, Sanchez-Sanchez M, Soria B, Cladera A, Artola M, Garcia-Guinon A, Gimenez-Conca A, Amador M, Martinez-Sanchez P, Algarra J, Vidal M, Alonso N, Maluquer C, Llorente L, Garcia-Boyero R, Ciudad J, Feliu E, Orfao A, PETHEMA Grp. Hematological Oncology. 2021 Oct;39(4):529-538. doi: 10.1002/hon.2910. PMID: 34405901

The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the PETHEMA-FLUGAZA phase 3 clinical trial. Ayala R, Rapado I, Onecha E, Martinez-Cuadron D, Carreno-Tarragona G, Bergua J, Vives S, Algarra J, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lorenzo J, Vidriales M, Labrador J, Falantes J, Sayas M, Paiva B, Barragan E, Prosper F, Sanz M, Martinez-Lopez J, Montesinos P, PETHEMA Cooperative Study Grp. Cancers. 2021 May 18;13(10):2458. doi: 10.3390/cancers13102458. PMID: 34070172

+ Info
Title: Significado pronóstico de la expresión del factor de crecimiento endotelial vascular (VEGF) y de genes implicados en las vías de señalización del VEGF en pacientes con leucemia aguda mieloblástica
Doctoral candidate: Calabuig Muñoz, Marisa
Director(s): Tormo Díaz, Mar; Solano Vercet, Carlos
Date of the defense: 04/05/2022
University: Universitat de València

Title: Análisis de la relación coste-efectividad del tratamiento con azacitidina en pacientes con síndrome mielodisplásico en el hospital clínico universitario de valencia
Doctoral candidate: Torrecilla Junyent, Teresa
Director(s): Alós Almiñana, Manuel; Tormo Díaz, María del Mar; Cortijo Gimeno, Julio
Date of the defense: 12/06/2019
University: Universitat de València